Passage Bio, Inc. · NASDAQ:PASG
Passage Bio — Investor Presentation (August 2024)
29 slides from Passage Bio's investor presentation, Aug 8, 2024
Slide 1: Corporate Presentation August 2024
Nasdaq: PASG © 2024 Passage Bio. All rights reserved. Corporate Presentation August 2024
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipat
Slide 3: Redefining the Course of Neurodegenerative Conditions
3 REDEFINING THE COURSE OF NEURODEGENERATIVE CONDITIONS Advancing potential best-in-class, one-time progranulin raising FTD-GRN gene therapy In-house manufacturing process development to support program execution Strong cash position with runway expected to the end of 2Q 2026* Exploring benefits of
Slide 4: Validating the Therapeutic Potential of PBFT02
4 Validating the Therapeutic Potential of PBFT02 Promising data from initial clinical study of PBFT02 in FTD-GRN Genetic form of FTD caused by GRN mutations, which lead to progranulin (PGRN) deficiency No approved disease-modifying therapies One-time therapy Proprietary AAV1 construct Nonsurgical in
Slide 5: Significant Market Opportunity for PBFT02 Across Multiple Neurodegenerative Diseases
5 Significant Market Opportunity for PBFT02 Across Multiple Neurodegenerative Diseases ~18,000 ~21,000 ~72,600 ~3.9M FTD-GRN1–3 FTD-C9orf722–4 AMYOTROPHIC LATERAL SCLEROSIS (ALS) 5–6 ALZHEIMER’S DISEASE (GRN SNP)*7–8 * rs5848 single nucleotide polymorphism (SNP) 1. Greaves CV, et al. J Neurol 2019;
Slide 6: Anticipated Upcoming Milestones and Data Readouts
6 Anticipated Upcoming Milestones and Data Readouts 2H 2024 1H 2025 2H 2025 Obtain regulatory feedback on the pathway to treating ALS patients Present updated safety and biomarker data from Cohort 1 patients at ISFTD2024 (Sep) Report 12-month Cohort 1 and interim Cohort 2 data FTD-GRN Milestones FTD
Slide 7: PBFT02 Frontotemporal Dementia-GRN
PBFT02 Frontotemporal Dementia-GRN
Slide 8: FTD: A Devastating Adult Disease
8 FTD: A Devastating Adult Disease OVERVIEW • Fatal adult-onset neurodegenerative disease affecting the frontal and temporal lobes of the brain, characterized by a decline in behavior, language and executive function • One of the most common causes of early-onset dementia worldwide, disproportionate
Slide 9: Progranulin Deficiency is the Defining Characteristic of FTD-GRN
9 Progranulin Deficiency is the Defining Characteristic of FTD-GRN and Leads to Neurodegeneration Progranulin is critical to maintaining CNS cell homeostasis Rhinn H et al. Trends Pharm Sci. 2022, 43:641-652.
Slide 10: Elevated PGRN Increases Potential for Improved Cellular Function
10 Elevated PGRN Increases Potential for Improved Cellular Function • Progranulin is a secreted protein that binds to cell membrane receptors to affect multiple intracellular pathways –Major role is regulating intracellular lysosomal activity –Extracellular PGRN is endocytosed via multiple receptors
Slide 11: Preclinical: AAV1 Achieved the Highest Levels of CSF PGRN in NHPs
11 Preclinical: AAV1 Achieved the Highest Levels of CSF PGRN in NHPs AAV1 increased CSF PGRN levels ~5x more than AAV5 and AAVhu68 (proprietary AAV9 variant) vectors, without further elevating peripheral levels Production of Human PGRN in Plasma AAV1 transgene delivery led to highest hPGRN levels in
Slide 12: Preclinical: Higher CSF PGRN May Confer Reduction in Inflammatory Response
12 Preclinical: Higher CSF PGRN May Confer Reduction in Inflammatory Response • Microgliosis: inflammatory response to pathogenic insults in the CNS • CD68: marker of activated microglia Thalamus data shown above. Thalamic atrophy is a key feature commonly found in FTD PBFT02 reduced lipofuscin at a
Slide 13: upliFT-D: Global Phase 1/2 Trial with PBFT02
13 upliFT-D: Global Phase 1/2 Trial with PBFT02 DURATION 2 years; with additional 3 years of follow-up for safety and durability of effect PRIMARY ENDPOINTS Safety and tolerability SECONDARY ENDPOINTS Biomarkers • Progranulin (CSF, plasma) • GFAP (CSF, plasma) • vMRI • Retinal nerve fiber layer and
Slide 14: Intra-Cisterna Magna (ICM) Administration
14 Intra-Cisterna Magna (ICM) Administration • Directly deliver vector into the CSF via a single injection to reach both CNS and peripheral tissues1 –Allows for broad CNS biodistribution –Lower doses compared to IV systemic delivery –Reduced impact of neutralizing antibodies • Brief (<60 min), non-s
Slide 15: upliFT-D: Interim Data from Cohort Patients
15 upliFT-D: Interim Data from Cohort 1 Patients • PBFT02 was well-tolerated among the four patients (P2-5) who received revised immunosuppression regimen –Among these patients, there were no SAEs; only mild-to-moderate treatment emergent AEs were reported • No evidence of DRG toxicity, as measured
Slide 16: Initial Patients Treated with PBFT02 Have Seen a Substantial Increase in CSF PGRN
16 • Potential best-in-class PGRN profile at Dose 1 • Continued elevation of CSF PGRN at 6-months (n=2) • Consistent response across first three treated patients Initial Patients Treated with PBFT02 Have Seen a Substantial Increase in CSF PGRN At Dosing D30 D60 D180 Patient 1 1.9 12.7 N/A N/A Patien
Slide 17: Plasma PGRN Levels Remained Below Normal Levels Post-Dose
17 • Plasma PGRN levels remained below normal levels at up to 6 months post-dose • PGRN increased only in the CSF where it has potential to correct deficit associated with neurodegeneration Plasma PGRN Levels Remained Below Normal Levels Post-Dose Shading: Lower limit of normal reference range for h
Slide 18: Summary
18 Summary SAFETY1 PBFT02 Dose 1 generally well-tolerated to date among the four Cohort 1 patients who received revised steroid regimen following protocol amendment • No serious AEs • All AEs mild to moderate in intensity • No evidence of clinically significant immune response, hepatotoxicity or ven
Slide 19: Looking Ahead
Looking Ahead Passage Bio
Slide 20: PBFT02 has Potential to Correct Underlying Pathology in FTD-GRN, FTD-C9orf72 and ALS
20 PBFT02 has Potential to Correct Underlying Pathology in FTD-GRN, FTD-C9orf72 and ALS TDP-43 pathology is a hallmark of multiple neurodegenerative diseases1 • TDP-43 mislocalizes from nucleus to cytoplasm • Forms inclusion bodies associated with neurodegeneration 1. Rhinn H et al. Trends Pharm Sci
Slide 21: Elevated PGRN Ameliorates TDP-43 Pathology in Preclinical Models
21 TDP-43 pathology due to lysosomal dysfunction (GRN/ TMEM106 double knockout, DKO) reduced by AAV.hPGRN1 Elevated PGRN Ameliorates TDP-43 Pathology in Preclinical Models AAV delivered hPGRN to DKO mouse brain TDP-43 pathology in DKO mice reduced by AAV.hPGRN Elevated PGRN reduced insoluble TDP-43
Slide 22: Decreased PGRN Associated with Greater Disease Severity in Multiple CNS Conditions
22 GRN rs5848 SNP associated with accelerated disease in FTD-C9orf72 patients Decreased PGRN Associated with Greater Disease Severity in Multiple CNS Conditions GRN rs5848 SNP associated with accelerated disease in FTD-C9orf72 patients 1. van Blitterswijk et al (2014) Mol Neurodegen. AD=Alzheimer’s
Slide 23: PBFT02 has Potential to Modulate Alzheimer's Disease
23 • GRN SNP rs5848 carriers have reduced PGRN levels and increased risk for AD • AD patients with GRN SNP rs5848 show reduced PGRN levels and increased CSF tau • GRN SNP rs5848 is estimated to occur in 30% of the general population, with a similar prevalence rate among AD patients2 • PGRN ablation
Slide 24: Leading In-House CMC Capabilities to Support PBFT02 Development
24 Leading In-House CMC Capabilities to Support PBFT02 Development Proven analytical development capabilities In-House CMC Analytical Capabilities to Support Program Advancement and Future Commercialization of PBFT02 Integrated process development GMP QC capabilities Strong regulatory CMC scientific
Slide 25: Upcoming Milestones and Corporate Updates
25 Upcoming Milestones and Corporate Updates PIPELINE • Advancing Huntington’s disease preclinical program • Licensed pediatric clinical-stage programs (GM1, Krabbe and MLD) to GEMMA Biotherapeutics BALANCE SHEET • Cash balance of $92 million as of 6/30/24* • Cash runway to the end of 2Q 2026* * Bas
Slide 26: Redefining the Course of Neurodegenerative Conditions
26 REDEFINING THE COURSE OF NEURODEGENERATIVE CONDITIONS Advancing potential best-in-class, one-time progranulin raising FTD-GRN gene therapy In-house manufacturing process development to support program execution Strong cash position with runway expected to the end of 2Q 2026* Exploring benefits of
Slide 27: Thank You
Thank You passagebio.com | NASDAQ: PASG
Slide 28: Focused Pipeline Addressing Rare and Prevalent Neurodegenerative Indications
28 Focused Pipeline Addressing Rare and Prevalent Neurodegenerative Indications Program Indication US/EU prevalence Discovery Preclinical Phase 1/2 Pivotal PBFT02 Frontotemporal dementia - GRN 18,0001-3 Frontotemporal dementia - C9orf72 21,0002-4 Amyotrophic lateral sclerosis 72,6005-6 Alzheimer’s d
Slide 29: Demonstrated Leadership
29 Demonstrated Leadership LEADERSHIP TEAM Deep experience in rare disease, CNS disorders and genetic medicines Eden Fucci SVP Technical Operations BOARD OF DIRECTORS Maxine Gowen, Ph.D. Chairwoman Athena Countouriotis, M.D. Avenzo Therapeutics Derrell Porter, M.D. cTRL Therapeutics Dolan Sondhi, Ph